B Lymphocyte Stimulator-directed Antibody Interactions [MoA] - N0000182636

Pharmacologic Class Information

Pharmacologic Code N0000182636
Pharmacologic Name B Lymphocyte Stimulator-directed Antibody Interactions
Pharmacologic Uses
  • B-Lymphocyte stimulator (BLyS)-specific inhibitor
Pharmacologic Concept Mechanisms of Action - [MoA]
Pharmacologic Concept Description This concept refers to the mechanism of action pharmacologic action at the receptor, membrane, or tissue level. In MED-RT, molecular, subcellular, or cellular effects of drug generic ingredients, organized into a chemical function classification hierarchy, beneath the "Cellular or Molecular Interactions" concept.

NDC Products with B Lymphocyte Stimulator-directed Antibody Interactions

The following table contains 3 products whose active ingredient are classified under the same pharmacologic class B Lymphocyte Stimulator-directed Antibody Interactions [MoA].

NDC Proprietary Name Non-Proprietary Name Dosage Form Route Name Company Name Status
49401-088Benlysta Non-Proprietary Name: BelimumabSolutionSubcutaneousGlaxosmithkline LlcACTIVE
49401-101Benlysta Non-Proprietary Name: BelimumabInjection, Powder, Lyophilized, For SolutionIntravenousGlaxosmithkline LlcACTIVE
49401-102Benlysta Non-Proprietary Name: BelimumabInjection, Powder, Lyophilized, For SolutionIntravenousGlaxosmithkline LlcACTIVE